Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations
- 15 April 2011
- journal article
- Published by Taylor & Francis in Cell Cycle
- Vol. 10 (8) , 1192-1199
Abstract
Utilizing the concept of synthetic lethality has provided new opportunities for the development of targeted therapies, by allowing the targeting of loss of function genetic aberrations. In cancer c...Keywords
This publication has 94 references indexed in Scilit:
- Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibitionDNA Repair, 2011
- Mutations in BRCA2 and PALB2 in male breast cancer cases from the United StatesBreast Cancer Research and Treatment, 2010
- Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2Nature Structural & Molecular Biology, 2010
- Aurora‐A expressing tumour cells are deficient for homology‐directed DNA double strand‐break repair and sensitive to PARP inhibitionEMBO Molecular Medicine, 2010
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- PALB2 Links BRCA1 and BRCA2 in the DNA-Damage ResponseCurrent Biology, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Minding the gap: The underground functions of BRCA1 and BRCA2 at stalled replication forksDNA Repair, 2007
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998